Atrys Health (XMAD:ATRY) Total Long-Term Assets: €260.1 Mil (As of Dec. 2025)


XMAD:ATRY Atrys Health SA XMAD:ATRY
64 GF Score
Price €2.48
GF Value €3.14
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health Total Long-Term Assets?

Atrys Health XMAD:ATRY -0.80% 64 Total Long-Term Assets is €260.1 Mil as of Dec. 2025. GuruFocus rates XMAD:ATRY with a GF Score™ of 64/100 and a GF Value™ of €3.14 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Atrys Health's Total Long-Term Assets for the quarter that ended in Dec. 2025 was €260.1 Mil.

Atrys Health Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Atrys Health's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrys Health Total Long-Term Assets Chart

Atrys Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 462.53 602.18 528.13 495.01 260.08

Atrys Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 528.13 509.88 495.01 487.16 260.08
XMAD:ATRY
64GF Score
Atrys Health SA XMAD:ATRY
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrys Health Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €260.1 Mil mean?
Atrys Health (XMAD:ATRY) has a Total Long-Term Assets of €260.1 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Atrys Health and its competitors.
Is Atrys Health's Total Long-Term Assets too high?
Atrys Health's current Total Long-Term Assets is €260.1 Mil. Overall, Atrys Health has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Total Long-Term Assets compare to VRTX and REGN?
Atrys Health's Total Long-Term Assets of €260.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Atrys Health and its competitors. Atrys Health's current Total Long-Term Assets is €260.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.14, compared to a current price of €2.48 — trading 21.2% below its estimated fair value. The current Total Long-Term Assets is €260.1 Mil. Atrys Health's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Total Long-Term Assets is €260.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.48 is trading 21.2% below its estimated GF Value™ of €3.14. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • Total Long-Term Assets: €260.1 Mil
  • GF Value™: €3.14 vs. price of €2.48 (21.2% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
64GF Score

Get the complete analysis for XMAD:ATRY

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.48
Price
€3.14
GF Value